Login to Your Account



Merck Hands Betrixaban Back to Portola Pharmaceuticals

By Catherine Shaffer


Friday, March 25, 2011
Portola Pharmaceuticals Inc. is taking back its rights from Merck and Co. Inc. for betrixaban, a Factor Xa inhibitor being developed for stroke. Merck reviewed and reprioritized its late-stage investigational portfolio, and did not find a place for betrixaban. The return of rights to the Phase III-ready product gives Portola an opportunity to develop the drug independently.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription